Endocrine Abstracts

Elongation factor, RNA polymerase II, 2 (ELL2) is an RNA Pol II elongation factor with functional properties similar to ELL that can interact with the prostate tumor suppressor ELL-associated factor 2 (EAF2). In murine models, deletion of Ell2 induced prostate intraepithelial neoplasia similar to that induced by deletion of Eaf2. Since ELL2 and EAF2 can functionally interact and appear to have similar function in regulating prostate homeostasis, we investigated the impact of c...

Background: Graves’ disease (GD) is a common autoimmune disorder characterized by the production of autoantibodies targeting the thyroid, leading to hypothyroidism. It is widely accepted that B lymphocytes play a significant role in GD as they are the source of autoantibodies (TRAb) against the thyroid-stimulating hormone receptor (TSHR). Previously, we reported that B cells infiltrate the thyroid tissue of GD patients, and in this study we observed that the percentage of...

Background and aims: Dehydroepiandrosterone fatty acid esters (DHEA-FAEs) belong to a unique family of naturally occurring hydrophobic steroid hormone derivatives with long-lasting hormonal activity. DHEA-FAEs function through hydrolysis of DHEA-FAEs into free DHEA and further metabolized to biologically active steroids. The lysosomal acid lipase (LAL) mediates the intracellular hydrolysis of cholesterol esters. This study aims to study the possible role of LAL on the hydrolys...

Background and aims: Dehydroepiandrosterone (DHEA) is an important prohormone and precursor of all sex steroids. DHEA fatty acid esters (DHEA-FAEs) belong to a unique family of naturally occurring hydrophobic steroid hormone derivatives with long-lasting hormonal activity, which are exclusively transported in lipoproteins. In the circulation, DHEA is esterified in a reaction catalyzed by lecithin-cholesterol acyltransferase associated with HDL particles. The physiological role...

ObjectiveIn BALB/c mice with GD model, the TSHR and ICAM-1 were targeted for treatment, and new approaches to GD targeted therapy were explored.MethodsThe siRNA targeting TSHR and the ICAM-1 mAb specifically binding ICAM-1 were designed and synthesized. Thirty GD model mice were randomly divided into siRNA treatment group, ICAM-1 mAb treatment group, and untreated GD group, with 10 mice in each group, and 10 ...

Background: Patients with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (panNET) are in need of novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is one of the key oncogenic drivers in neuroendocrine tumors. Hypoxia signaling pathway alterations or other mechanisms that stabilize HIFs are common in some PPGLs and panNETs. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in advanced renal cell...